SciBase – Interim report

0
37

The first quarter in figures

  • Net sales amounted to TSEK 2,562 (2,469).
  • The loss after tax amounted to TSEK 8,153 (8,936).
  • The loss per share amounted to SEK 0.15 (0.54).
  • The cash flow from current operations was negative in the amount of TSEK 9,473 (7,893).
  • The gross margin reached 52.7% (54.0%).
  • Electrode sales volume increased by 14% and reached 7,496 (6,562) units, a new quarterly high. Repeat sales of electrodes to existing customers increased by 18%.

Important events during the quarter

  • Covid-19 continues to affect sales and the market situation remains difficult to predict going forward, due to ongoing lockdowns and reduced marketing activities. Sales in the company’s key market Germany increased by 3%(cleared for currency effects +9%) while overall sales increased by 3% (cleared for currency effects +9%).
  • A further German study evaluating the value of using Nevisense on suspected Non-melanoma skin cancer (NMSC, also known as Keratinocyte cancer) in normal clinical practice was published.
  • David Melin, SciBase’s head of product development, has chosen to leave his position and accept a role at another company. The Company is now looking for the right profile to take the product/technology platform forward.
  • A nominating committee was appointed.

Important events after the end of the  period

  • SciBase submitted the first US reimbursement application to CMS’s Medicare Contractor in Florida, First Coast Service Options (FCSO). The application for Medicare coverage in Florida marks an important step in the reimbursement process for SciBase and is a necessary step towards broader penetration and usage of the Nevisense test.
  • SciBase received certification under the new Medical Device Regulation (MDR).
  • The new Non-Melanoma Skin Cancer (NMSC) clinical application was launched following the completion of the MDR certification process.
  • A groundbreaking article by key SciBase collaborator Professor Cezmi Akdis presenting the “epithelial barrier hypothesis” was published in Nature Reviews Immunology. The article presented the background for the steep increase in allergic and other diseases over the last decades, and how this increase is connected to degradation in barrier function in the body.
  • A new clinical study from the Swiss Institute of Allergy and Asthma Research (SIAF) was published in the European Journal of Allergy and Clinical Immunology (Allergy). In the study Nevisense was used to assess the skin barrier of patients with atopic dermatitis (AD) and could accurately detect signs of barrier degradation in atopic patients, even in visually unaffected skin. Nevisense measurements also correlated with relevant biomarkers for atopic dermatitis.
  • The notice to attend the AGM 2021 was published as well as the nominating committees supplementary proposal to nominate Dr Matt Leavitt for the Board of Directors.
  • The annual report 2020 was published on April 9th.

                                   

Apr 1 2020 – 

                                   

Jan 1 – Mar 31

Mar 31 2021

                                   

Jan 1 – Dec 31                                              

                                   

THE GROUP

2021

2020

                                   

Rolling-12

2020

                                   

Net sales, SEK ths

2 562

2 496

9 588

9 521

                                   

Gross margin, %

52,7%

54,0%

52,2%

52,5%

                                   

Equity/Asset ratio, %

79,6%

64,8%

73,3%

79,1%

                                   

Net indebtness, multiple

0,26

0,54

0,36

0,26

                                   

Cash equivalents, SEK ths

31 403

17 970

31 403

41 427

                                   

Cashflow from operating activities, SEK ths

-9 473

-7 893

-35 441

-33 861

                                   

Earnings per share (before and after dilution), SEK

-0,15

-0,38

-0,84

-1,12

                                   

Shareholder’s equity per share, SEK

0,70

1,40

0,76

1,50

                                   

Average number of shares, 000′

54 780

16 618

40 828

31 287

                                   

Number of shares at closing of period, 000′

54 780

16 618

54 780

54 780

                                   

Share price at end of period, SEK

4,78

1,84

4,78

4,62

                                   

Number of sold electrodes, pieces

7 496

6 598

26 584

25 686

                                   

Average number of employees

18

16

17

16

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on May 12, 2021.

LEAVE A REPLY

Please enter your comment!
Please enter your name here